FLUIDDA's breakthrough imaging technology was used to assess the mode of action of Roflumilast, a novel drug to treat patients suffering from chronic obstructive pulmonary disease (COPD). FLUIDDA's ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
LOS ANGELES, March 23, 2020 /PRNewswire-PRWeb/ -- Worldwide Business with kathy ireland® is pleased to announce an exclusive interview with FLUIDDA that will be airing in 2020. FLUIDDA is the world ...
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced ...
FLUIDDA develops proprietary Functional Respiratory Imaging (FRI) technology that provides a unique entry point into personalized medicine for respiratory diseases. FRI reduces significantly the ...
LOS ANGELES, March 11, 2020 /CNW/ -- The US Food and Drug Administration provided market clearance to Fluidda for its Broncholab platform. Broncholab provides a number of Functional Respiratory ...
guide for physicians to determine which patient to treat. The results will soon be published in the renowned European Respiratory Journal. FLUIDDA's CEO Dr. Jan De Backer commented: "We are very happy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results